Artrite reumatóide tratada com enzimas sistêmicas -1

Size: px
Start display at page:

Download "Artrite reumatóide tratada com enzimas sistêmicas -1"

Transcription

1 Artrite reumatóide tratada com enzimas sistêmicas Clinical and immunological criteria of activity of different rheumatic arthritis courses and their treatment by Wobenzym. Siziakina L.P., Artemenko N.A. Clinical and immunological criteria of activity of different rheumatic arthritis courses and their treatment by Wobenzym. III. Internat. Congress on Immunorehabilitation and Rehabilitation in Medicine, Eilat, Israel,. Russian version Rheumatic arthritis (RA) is a chronical disease, its pathogenesity includes deep immune system disorders with a disbalance of qualitative and quantitative composition of immunocompetent cells including functional and cell cooperation disorders (8). Joint damage is the most obvious syndrome of rheumatic arthritis. But other symptoms than joint damage mostly determine an aggressivity of the disease and its prognosis. Role and place of different components of inflammation immune complex in a rheumatic arthritis process development is being currently discussed. A progresive character of the disease with a formation of irreversible joint and inner organ damage, an early invalidity of patients, and a decrease of working ability define a medical and social importance of this problem as well as a necessity of continuing study of clinicalpathogenetic peculiarities of rheumatic arthritis and a search for optimal treatment program. An important role in a rheumatic arthritis diagnosis plays a determination of IgGRF (rheumatic factor) which seems to be an autoantibody against IgG fragment (). Both an existence of serum negative variant of rheumatic factor and its detection in other rheumatic and nonrheumatic diseases determine a necessity to investigate RA serological markers, for example antibodies against cardiolipins (acl), associated with thromboses during rheumatic diseases, and antibody against native DNA (ndna) determining a formation of immunopathological component. In many cases a rheumatic arthritis course is complicated by systemic symptoms which cause a development of pathological process (3, 3). Various changes in rheological properties of blood during rheumatic arthritis cause damages of microcirculation and seem to be one of the factors which make the disease become chronic (, 0). Despite of different clinical symptoms of thrombohemorragical syndrome and expression of damages of rheological, coagulational, and fibrinolytical properties of blood (, 3, ), the most important way to diagnose changes in microcirculation is the use of immunological methods. Such methods include determination of antigen factor van Billebrand (FB) in blood plasma. FB is a macromolecular protein synthesized by the vascular endothelium cells which define a function of thrombocytes (TC) and an activity of VIII. coagulating factor structural part of which FB makes (). Except this, investigation of new pathogenetic mechanisms of a rheumatic arthritis formation, insufficient efficacy of existing preparations for treatment, and serious side effects (treatment by corticosteroids, nonsteroidal antirheumatic substances, cytostatics) show a need for new treatment methods of different types of rheumatic arthritis. patients ( men, 3 women) with reliable rheumatic arthritis (criteria of American Rheumatological Association, 8) were observed. An average age was. (from 3 to ) years. 38 patients were serum positive on IgMRF and were serum negative. patients showed activity of rheumatic arthritis corresponding to degree I, patients to degree II and patients to degree III. Confirmation of diagnosis by Xray for all patients is available (Table ). In 8 patients syndromes such as fever, rheumatic nodes, amiotrophic syndrome, damage of cardiovascular system, digestive system and others occured. In some cases concomitant diseases appeared: tuberculosis, malignant tumors, diabetes, periodical illness. During clinical observations of patients joint index, oedema index, joint sum (by Richi), functional test by Li and an intensity of hand clasp (mm.rt.st) were followed. All patients were subjected to a general clinical observation and also basic signs of immunological statute () were observed. Using IFA a titer of antibody against ndna was determined. IgMRF and a presence of antibody against cardiolipins and antigen factor von Billebrand (FB) were determined in patients serum (test of the AGAB system, Moscow).

2 Wobenzym (Mucos Pharma) was administred together with methotrexate mg on Sunday; 0 dragees three times a day, 0 minutes before meals days, then dragees three times a day days, followed by dragees three times a day 30 days. To observe an efficacy of the preparation, a group of 8 people (serum positive, joint form) was established. Control group included people treated with nonsteroidal antirheumatic substances and methotrexate ( mg). Results were evaluated statistically using nonparametrical criterium by MannWhitney. Observed group included 38 patients (8.%), positive on IgMRF, and (.%) serum negative patients. Comparison of clinical signs in both groups showed an absence of significant differences (Table II). In serum negative group dominated patients with inner organ damage 8.%, in serum positive group inner organ damage occured in.% patients. Presence of antibodies against cardiolipins was tested in serum positive group. A positive result was obtained in patients (3.%). In patients (0.8%) inner organ damage developed and only in patients (.%) joint form of rheumatic arthritis was diagnosed. Table I General clinical characterization of patients Signs Number of serum positive patients Number of serum negative patients Total number of patients Sex M F Age more than 0 Degree of activity I II III Functional I insufficiency II of joints III IV 3 0 Xray stadium I II III IV 3 Form joint with inner organ damage 8 Table II Basic clinical signs of joint syndrome Signs Serum positive patients Serum negative patients Joint index by Richi. + 0.* + 0.* Joint sum by Richi *. + 0.* Oedema index by Richi Functional index by Li * * Intensity of a hand clasp R. + 0.* *

3 (mm.rt.st.) L *. +.* * statistically significant differences p< 0.0 as compared to control A degree of autoimmune process activity can be derived from a titer of antibody against ndna. Among serum positive patients antibody against ndna was detected in patients (.%) 8 (3.%) with the joint form and (3.%) with the inner organ damage. In the serum negative group acl were detected in 8.% of patients (83.3% with the inner organ damage and only.% of patients with the joint form of rheumatic arthritis). Among observed patients antibody against ndna was detected in patients (.%). Interestingly, all of them had a rheumatic arthritis with inner organ damage (Table III). Table III Changes in signs of immunological statute dependent on a type of rheumatic arthritis course Groups Signs of immunological statute Sedimentation mm/hour CIC Titer of antibody against ndna, lg acl % Serum positive (IgM RF (+)) Serum negative (IgM RF ()) *. + 0.* * *.3 8. * statistically significant differences p< 0.0 From obtained results it can be concluded that acl occur in rheumatic arthritis patients sufficiantly frequently in.% of cases. In patients with inner organ damage acl were detected more often in 3.3%. In the groups of serum negative and serum positive patients on IgM RF, acl occured with the same frequency in 83.3% and 0.8%, respectively (Figure ). Figure : Frequency of an acl occurance in patients with rheumatic arthritis with different courses. Analysis of antibody against ndna showed that higher titer of the antibody appeared in rheumatic arthritis patients with inner organ damage.3%. When compared serum positive and serum negative groups, antibody against ndna was detected in approximately same number of patients.% and.%, resp. Based on the results of our investigation it could be concluded that inner organ damage (accompanied with an increase of polyclonal hyperglobulinemy, CIC level and of the titer of antibodies against ndna and acl) is considered to be an undesirable symptom caused by a high activity of autoimmune process. Therefore, there is a need for an improvement of the current treatment therapy. Serum negativity on IgMRF does not presume a favourable course of rheumatic arthritis with a high titer of antibody against ndna, high value of CIC and a presence of acl. Additionally, in such cases a positivity on IgG or IgARF is possible.

4 Clinical sign analysis of rheumatic arthritis patients, administred with methotrexate and Wobenzym, gave following results. In patients treated with Wobenzym a faster reduction of joint swelling, reduction of a degree of morning tightness and a lessening of Li index was observed compared to a control group (Figure ). Analysis of immunological statute signs showed that in patients treated with Wobenzym a more significant lessening of IgM level occured as well as a faster normalization of sedimentation. CIC degree remained higher ( Figure ). A faster clinical and immunological remission in patients treated with Wobenzym and methotrexate enabled to lessen a dosage of methotrexate to. mg. Two patients voluntarily gave up on methotrexate. During next three months an activation of pathological process did not occur. In the case of one patient an effect of Wobenzym treatment was negligible, glucocorticoids were therefore administred. Comparison of a treatment efficacy in Wobenzym group and a control group is shown in Figure 3. Figure : Signs of immunological statute in RA patients treated with and without Wobenzym. Figure 3: Effect of Wobenzym in the rheumatic arthritis treatment.

5 With regard to a higher CIC values after Wobenzym administration it is necessary to include a plasmapheresis during first month of treatment. Based on all above mentioned facts it can be concluded that a presence of antibodies against cardiolipins and ndna is associated with inner organ damage at IgMRF serum positive and serum negative rheumatic arthritis Rheumatic arthritis with inner organ damage, accompanied with an increased titer of antibody against ndna, CIC level and a presence of an antibody against cardiolipins, is considered a unfavourable course which needs a therapy improvement. An increase of ndna antibody titer, CIC level and a presence of antibodies against cardiolipins appear to be a more informative signs of an autoimmune process activity in comparison to general clinical observations. Therefore, it is suggested to use these immunological tests for prognosis of a disease course and for control of the therapy efficacy.

Rheumatoid Arthritis. Manish Relan, MD FACP RhMSUS Arthritis & Rheumatology Care Center. Jacksonville, FL (904)

Rheumatoid Arthritis. Manish Relan, MD FACP RhMSUS Arthritis & Rheumatology Care Center. Jacksonville, FL (904) Rheumatoid Arthritis Manish Relan, MD FACP RhMSUS Arthritis & Rheumatology Care Center. Jacksonville, FL (904) 503-6999. 1 Disclosures Speaker Bureau: Abbvie 2 Objectives Better understand the pathophysiology

More information

AUTOIMMUNITY CLINICAL CORRELATES

AUTOIMMUNITY CLINICAL CORRELATES AUTOIMMUNITY CLINICAL CORRELATES Pamela E. Prete, MD, FACP, FACR Section Chief, Rheumatology VA Healthcare System, Long Beach, CA Professor of Medicine, Emeritus University of California, Irvine Colonel

More information

AUTOIMMUNITY TOLERANCE TO SELF

AUTOIMMUNITY TOLERANCE TO SELF AUTOIMMUNITY CLINICAL CORRELATES Pamela E. Prete, MD, FACP, FACR Section Chief, Rheumatology VA Healthcare System, Long Beach, CA Professor of Medicine, Emeritus University of California, Irvine Colonel

More information

Use of Serological markers for evaluation of patients with Rheumatoid arthritis

Use of Serological markers for evaluation of patients with Rheumatoid arthritis ISSN: 2319-7706 Volume 4 Number 9 (2015) pp. 61-66 http://www.ijcmas.com Original Research Article Use of Serological markers for evaluation of patients with Rheumatoid arthritis G. Sucilathangam*, G.

More information

1.0 Abstract. Title. Keywords. Rationale and Background

1.0 Abstract. Title. Keywords. Rationale and Background 1.0 Abstract Title A Prospective, Multi-Center Study in Rheumatoid Arthritis Patients on Adalimumab to Evaluate its Effect on Synovitis Using Ultrasonography in an Egyptian Population Keywords Synovitis

More information

Understanding Rheumatoid Arthritis

Understanding Rheumatoid Arthritis Understanding Rheumatoid Arthritis Understanding Rheumatoid Arthritis What Is Rheumatoid Arthritis? 1,2 Rheumatoid arthritis (RA) is a chronic autoimmune disease. It causes joints to swell and can result

More information

When is it Rheumatoid Arthritis When to Refer

When is it Rheumatoid Arthritis When to Refer When is it Rheumatoid Arthritis When to Refer Nancy A. Brown, DO Spring 2015 When is it Rheumatoid Arthritis When to Refer Learning objectives To review the definition and epidemiology of Rheumatoid Arthritis

More information

Rheumatoid arthritis

Rheumatoid arthritis Rheumatoid arthritis 1 Definition Rheumatoid arthritis is one of the most common inflammatory disorders affecting the population worldwide. It is a systemic inflammatory disease which affects not only

More information

Manifestation of Antiphospholipid Syndrome among Saudi patients :examining the applicability of sapporo Criteria

Manifestation of Antiphospholipid Syndrome among Saudi patients :examining the applicability of sapporo Criteria Manifestation of Antiphospholipid Syndrome among Saudi patients :examining the applicability of sapporo Criteria Farjah H AlGahtani Associate professor,md,mph Leukemia,Lymphoma in adolescent,thromboembolic

More information

MDP on Improving Refractory Ankylosing Spondylitis Symptoms of Erythrocyte Sedimentation Rate and CRP. Guo Dan, Shuai Ping

MDP on Improving Refractory Ankylosing Spondylitis Symptoms of Erythrocyte Sedimentation Rate and CRP. Guo Dan, Shuai Ping 5th International Conference on Advanced Materials and Computer Science (ICAMCS 2016) MDP on Improving Refractory Ankylosing Spondylitis Symptoms of Erythrocyte Sedimentation Rate and CRP Guo Dan, Shuai

More information

Cimzia (certolizumab pegol) Data Showed Broad and Rapid Relief From Burden of Symptoms In Rheumatoid Arthritis Patients

Cimzia (certolizumab pegol) Data Showed Broad and Rapid Relief From Burden of Symptoms In Rheumatoid Arthritis Patients Cimzia (certolizumab pegol) Data Showed Broad and Rapid Relief From Burden of Symptoms In Rheumatoid Arthritis Patients Rapid, sustained and clinically meaningful improvement in wideranging patient-reported

More information

Summary of Risk Minimization Measures

Summary of Risk Minimization Measures Table 6.1.4-1: Summary of Risk Minimization Measures Safety Concern Vaccination Hepatic and renal impairment Combination therapy Elderly Routine Risk Minimization Measures Specific subsection on vaccination

More information

ISSN: CODEN Code: PIHNBQ ZDB-Number: IC Journal No: Vol. 2 No Online Available at

ISSN: CODEN Code: PIHNBQ ZDB-Number: IC Journal No: Vol. 2 No Online Available at Received: 27-08-2013 Accepted: 29-09-2013 ISSN: 2277-7695 CODEN Code: PIHNBQ ZDB-Number: 2663038-2 IC Journal No: 7725 Vol. 2 No. 10 2013 Online Available at www.thepharmajournal.com THE PHARMA INNOVATION

More information

University of Pretoria

University of Pretoria University of Pretoria Serodiagnostic Procedures Performed in the Department of Immunology Dr Pieter WA Meyer 1.Autoimmune Diseases Automated Anti-nuclear antibodies Anti-gliadin/ tissue transglutaminase

More information

New Cimzia data, with sites in the US, demonstrate safety and efficacy, increased participation in social activities for adult RA patients

New Cimzia data, with sites in the US, demonstrate safety and efficacy, increased participation in social activities for adult RA patients Long-term Cimzia (certolizumab pegol) data demonstrated rapid sustained improvements in clinical outcomes and quality of life in moderate to severe rheumatoid arthritis (RA) patients New Cimzia data, with

More information

Remicade (Infliximab)

Remicade (Infliximab) Remicade (Infliximab) Policy Number: Original Effective Date: MM.04.016 11/18/2003 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 07/26/2013 Section: Prescription Drugs Place(s)

More information

Coccidioidomycosis in Rheumatologic Patients. Susan E. Hoover, MD

Coccidioidomycosis in Rheumatologic Patients. Susan E. Hoover, MD Coccidioidomycosis in Rheumatologic Patients Susan E. Hoover, MD The problem Prevalence of rheumatoid arthritis is 1% Population of Arizona is 6 million At least 150,000 new cocci infections yearly DMARDs

More information

THICK AS THIEVES: A CURIOUS CASE OF SJOGREN S SYNDROME. Sophie Wojcik, Dr Murray Baron PGY5 Rheumatology McGill University Friday May 11 th 2018

THICK AS THIEVES: A CURIOUS CASE OF SJOGREN S SYNDROME. Sophie Wojcik, Dr Murray Baron PGY5 Rheumatology McGill University Friday May 11 th 2018 THICK AS THIEVES: A CURIOUS CASE OF SJOGREN S SYNDROME Sophie Wojcik, Dr Murray Baron PGY5 Rheumatology McGill University Friday May 11 th 2018 DISCLOSURES! No relevant disclosures MRS H! 34 y.o. woman,

More information

How the Innate Immune System Profiles Pathogens

How the Innate Immune System Profiles Pathogens How the Innate Immune System Profiles Pathogens Receptors on macrophages, neutrophils, dendritic cells for bacteria and viruses Broad specificity - Two main groups of bacteria: gram positive, gram-negative

More information

Monoclonal Antibodies in the Management of Rheumatoid Arthritis Prof. John D. Isaacs

Monoclonal Antibodies in the Management of Rheumatoid Arthritis Prof. John D. Isaacs John D Isaacs Professor of Clinical Rheumatology Director, Wilson Horne Immunotherapy Centre Newcastle University, UK 1 Rheumatoid arthritis Targeting T-cells Targeting B-cells Costimulation blockade Novel

More information

New Evidence reports on presentations given at ACR Improving Radiographic, Clinical, and Patient-Reported Outcomes with Rituximab

New Evidence reports on presentations given at ACR Improving Radiographic, Clinical, and Patient-Reported Outcomes with Rituximab New Evidence reports on presentations given at ACR 2009 Improving Radiographic, Clinical, and Patient-Reported Outcomes with Rituximab From ACR 2009: Rituximab Rituximab in combination with methotrexate

More information

Learning about Lupus. Learning About Lupus. Lupus Society of Illinois

Learning about Lupus. Learning About Lupus. Lupus Society of Illinois Learning About Lupus Learning about Lupus Lupus Society of Illinois 525 W. Monroe Street, Suite 900 Chicago, Illinois 60661 Robert S. Katz, M.D. Professor of Medicine Rush University Medical Center Northwestern

More information

Simponi / Simponi ARIA (golimumab)

Simponi / Simponi ARIA (golimumab) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 6 Last Review Date: September 15, 2016 Simponi / Simponi

More information

Rheumatoid Arthritis. Improving Outcomes in RA: Three Pillars. RA: Chronic Joint Destruction and Disability What We Try to Prevent

Rheumatoid Arthritis. Improving Outcomes in RA: Three Pillars. RA: Chronic Joint Destruction and Disability What We Try to Prevent Rheumatoid Arthritis Modern Management of Common Problems in Rheumatology: Rheumatoid Arthritis Jonathan Graf, M.D. Associate Professor of Medicine, UCSF Division of Rheumatology, SFGH Director, UCSF Rheumatoid

More information

Rheumatoid Arthritis. Module III

Rheumatoid Arthritis. Module III Rheumatoid Arthritis Module III Management: Biological disease modifying anti-rheumatic drugs, glucocorticoids and special situations (pregnancy & lactation) Dr Ved Chaturvedi MD, DM Senior Consultant

More information

Pharmaceutical pathology

Pharmaceutical pathology Pharmaceutical pathology Livia Vida 2018 1. Necrosis, types, examples. Apoptosis. 2. Adaptations I. Degeneration, atrophy. 3. Adaptations II. Hypertrophy, hyperplasia. 4. Pigments. Calcification. 5. Inflammation

More information

Lupus as a risk factor for cardiovascular disease

Lupus as a risk factor for cardiovascular disease Lupus as a risk factor for cardiovascular disease SØREN JACOBSEN Department Rheumatology, Rigshospitalet Søren Jacobsen Main sponsors: Gigtforeningen Novo Nordisk Fonden Rigshospitalet Disclaimer: Novo

More information

2nd International Conference on Predictive, Preventive and Personalized Medicine & Molecular Diagnostics. November 03-05, 2014, Las Vegas, USA

2nd International Conference on Predictive, Preventive and Personalized Medicine & Molecular Diagnostics. November 03-05, 2014, Las Vegas, USA Kirill Shlyapnikov, MD, Echinacea Clinic, Russia, Moscow Fibromyalgia and Chronic Fatigue Syndrome: Pathogenesis, Detecting Predisposed Persons, Preventive and Rehabilitation Treatment 2nd International

More information

ANTICARDIOLIPIN ANTIBODIES IN PATIENTS WITH RHEUMATIC DISEASES

ANTICARDIOLIPIN ANTIBODIES IN PATIENTS WITH RHEUMATIC DISEASES 752 ANTICARDIOLIPIN ANTIBODIES IN PATIENTS WITH RHEUMATIC DISEASES JOHN G FORT, F SUSAN COWCHOCK, JOHN L ABRUZZO, and J BRUCE SMITH Recent attention has focused on the presence of anticardiolipin (ACL)

More information

Etiology: Pathogenesis Clinical manifestation Investigation Treatment Prognosis

Etiology: Pathogenesis Clinical manifestation Investigation Treatment Prognosis Etiology: Pathogenesis Clinical manifestation Investigation Treatment Prognosis JIA is the most common rheumatic disease in childhood and a major cause of chronic disability. Etiology: Unknown, but may

More information

Inflammatory rheumatic diseases

Inflammatory rheumatic diseases Learning objectives Inflammatory rheumatic diseases Bruce Kidd Barts & The London, Queen Mary, University of London To understand: 1. prevalence and range of the rheumatological s 2. clinical features

More information

PHM142 Autoimmune Disorders + Idiosyncratic Drug Reactions

PHM142 Autoimmune Disorders + Idiosyncratic Drug Reactions PHM142 Autoimmune Disorders + Idiosyncratic Drug Reactions 1 Autoimmune Disorders Auto-reactivity: low physiological levels (e.g. tolerance) vs. pathogenic levels 80+ types of autoimmune diseases affect

More information

DRAFT. Remission rates, calculated using observed case (OC) analyses were as follows: Year 1 Year 2 Year 3 Year 4 All patients 62.

DRAFT. Remission rates, calculated using observed case (OC) analyses were as follows: Year 1 Year 2 Year 3 Year 4 All patients 62. DRAFT New Efficacy Data Shows Cimzia (certolizumab pegol) Provides Long-Term Remission of Moderate to Severe Crohn s Disease Regardless of Prior Anti-TNF Exposure, According to Data Presented at DDW Oral

More information

Diagnostic and prognostic serological analyses in RA

Diagnostic and prognostic serological analyses in RA 9/9/ Diagnostic and prognostic serological analyses in RA Johan Rönnelid Clinical Immunology and Transfusion medicine Akademiska sjukhuset, Uppsala Department of Immunology, Genetics and Pathology Uppsala

More information

Opinion 23 July 2014

Opinion 23 July 2014 The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 23 July 2014 IMUREL 50 mg, film-coated tablet (B/100) (CIP: 34009 364 149 0 7) IMUREL 25 mg, film-coated tablet (B/50)

More information

Test Name Results Units Bio. Ref. Interval

Test Name Results Units Bio. Ref. Interval 135091662 Age 45 Years Gender Male 29/8/2017 120000AM 29/8/2017 100215AM 29/8/2017 110825AM Ref By Final RHEUMATOID AUTOIMMUNE COMREHENSIVE ANEL ANTI NUCLEAR ANTIBODY / FACTOR (ANA/ANF), SERUM ----- 20-60

More information

3.Autoimmunity. a. Self-recognition of all body components. a. Auto-antibody directed against a self antigen.

3.Autoimmunity. a. Self-recognition of all body components. a. Auto-antibody directed against a self antigen. 3.Autoimmunity I. Introduction A. Introduction 1. Normal individuals do not produce destructive immune responses to their own tissues due to immune tolerance. a. Self-recognition of all body components.

More information

Regulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of:

Regulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of: Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 8 Last Review Date: March 17, 2017 Simponi / Simponi

More information

Clinical Study Evaluation and Clinical Validity of a New Questionnaire for Mikulicz s Disease

Clinical Study Evaluation and Clinical Validity of a New Questionnaire for Mikulicz s Disease International Rheumatology Volume 2, Article ID 283459, pages doi:1.1155/2/283459 Clinical Study Evaluation and Clinical Validity of a New Questionnaire for Mikulicz s Disease Motohisa Yamamoto, 1 Hiroki

More information

Treatment of Rheumatoid Arthritis: The Past, the Present and the Future

Treatment of Rheumatoid Arthritis: The Past, the Present and the Future Treatment of Rheumatoid Arthritis: The Past, the Present and the Future Lai-Ling Winchow FCP(SA) Cert Rheum(SA) Chris Hani Baragwanath Academic Hospital University of the Witwatersrand Outline of presentation

More information

Clinical Laboratory. [None

Clinical Laboratory. [None Clinical Laboratory Procedure Result Units Ref Interval Accession Collected Received Double-Stranded DNA (dsdna) Ab IgG ELISA Detected * [None 18-289-900151 Detected] Double-Stranded DNA (dsdna) Ab IgG

More information

Autoantibodies in the Idiopathic Inflammatory Myopathies

Autoantibodies in the Idiopathic Inflammatory Myopathies Autoantibodies in the Idiopathic Inflammatory Myopathies Steven R. Ytterberg, M.D. Division of Rheumatology Mayo Clinic Rochester, MN The Myositis Association Annual Conference St. Louis, MO Sept. 25,

More information

HENOCH SCHÖNLEIN PURPURA (VASCULAR PURPURA, ANAPHYLACTOID PURPURA) IN CHILDREN Single choice tests (SC)

HENOCH SCHÖNLEIN PURPURA (VASCULAR PURPURA, ANAPHYLACTOID PURPURA) IN CHILDREN Single choice tests (SC) HENOCH HÖNLEIN PURPURA (VAULAR PURPURA, ANAPHYLACTOID PURPURA) IN CHILDREN Single choice tests () 1. Choose the type of bleeding characteristic for the Henoch Schönlein purpura (vascular purpura, anaphylactoid

More information

Laboratory Procedure Handout RHEUMATOID FACTORS

Laboratory Procedure Handout RHEUMATOID FACTORS KING ABDULAZIA UNIVERSITY FACULTY OF APPLIED MEDICAL SCIENCES DEPARTEMENT OF LABORATORY MEDICAL TECHNOLOGY Laboratory Procedure Handout RHEUMATOID FACTORS RF Latex agglutination for detection of RF INTRODUCTION

More information

ACTEMRA (tocilizumab)

ACTEMRA (tocilizumab) ACTEMRA (tocilizumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs

More information

Efficacy and Safety of Belimumab in the treatment of Systemic Lupus Erythematosus: a Prospective Multicenter Study.

Efficacy and Safety of Belimumab in the treatment of Systemic Lupus Erythematosus: a Prospective Multicenter Study. 1. Title Efficacy and Safety of Belimumab in the treatment of Systemic Lupus Erythematosus: a Prospective Multicenter Study. 2. Background Systemic Lupus Erythematosus (SLE) is a chronic, autoimmune and

More information

Supplemental Table 1. Key Inclusion Criteria Inclusion Criterion OPTIMA PREMIER 18 years old with RA (per 1987 revised American College of General

Supplemental Table 1. Key Inclusion Criteria Inclusion Criterion OPTIMA PREMIER 18 years old with RA (per 1987 revised American College of General Supplemental Table 1. Key Inclusion Criteria Inclusion Criterion OPTIMA PREMIER 18 years old with RA (per 1987 revised American College of General Rheumatology classification criteria) 34 ; erythrocyte

More information

Effective Health Care Program

Effective Health Care Program Comparative Effectiveness Review Number 55 Effective Health Care Program Drug Therapy for Rheumatoid Arthritis in Adults: An Update Executive Summary Background Rheumatoid arthritis (RA), which affects

More information

Regulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)

Regulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 9 Last Review Date: March 16, 2018 Simponi / Simponi

More information

High Impact Rheumatology

High Impact Rheumatology High Impact Rheumatology Systemic Lupus Erythematosus Bernard Rubin, DO MPH Case 1: History A 45-year-old woman presents with severe dyspnea and cough. She was in excellent health until 4 weeks ago when

More information

American College of Rheumatology (ACR) Updated Guideline for the Management of Rheumatoid Arthritis. Public Comments

American College of Rheumatology (ACR) Updated Guideline for the Management of Rheumatoid Arthritis. Public Comments The ACR public comment was posted on the ACR website October 30, 2018. The announcement was e-mailed to the Practice Guidelines Subcommittee, Quality of Care Committee and ACR Board of Directors, and was

More information

Diseases of Immunity 2017 CL Davis General Pathology. Paul W. Snyder, DVM, PhD Experimental Pathology Laboratories, Inc.

Diseases of Immunity 2017 CL Davis General Pathology. Paul W. Snyder, DVM, PhD Experimental Pathology Laboratories, Inc. Diseases of Immunity 2017 CL Davis General Pathology Paul W. Snyder, DVM, PhD Experimental Pathology Laboratories, Inc. Autoimmunity Reflects a loss of immunologic tolerance Mechanisms Auto-antibodies

More information

Pain or stiffness in joints after periods of inactivity or excessive use

Pain or stiffness in joints after periods of inactivity or excessive use Arthritis Awareness* Some older adults call it Arthur ; others refer to it as their constant compassion, but most describe it as extremely painful Arthritis is a chronic joint disease It is commonly believed

More information

IdentRA test panel with eta. A clinically proven biomarker for earlier, accurate RA diagnosis and now, prognosis and monitoring

IdentRA test panel with eta. A clinically proven biomarker for earlier, accurate RA diagnosis and now, prognosis and monitoring IdentRA test panel with 14-3-3eta A clinically proven biomarker for earlier, accurate RA diagnosis and now, prognosis and monitoring Did you know there are more than 100 forms of arthritis? Every type

More information

Kelley's Textbook of Rheumatology. 2 Volume Set. Text with Internet Access Code for Premium Consult Edition

Kelley's Textbook of Rheumatology. 2 Volume Set. Text with Internet Access Code for Premium Consult Edition Kelley's Textbook of Rheumatology. 2 Volume Set. Text with Internet Access Code for Premium Consult Edition Firestein, G ISBN-13: 9781437717389 Table of Contents VOLUME I STRUCTURE AND FUNCTION OF BONE,

More information

LABORATORY STANDARDS IN THE DIAGNOSIS AND THERAPY MONITORING OF SYSTEMIC LUPUS ERYTHEMATOSUS

LABORATORY STANDARDS IN THE DIAGNOSIS AND THERAPY MONITORING OF SYSTEMIC LUPUS ERYTHEMATOSUS LABORATORY STANDARDS IN THE DIAGNOSIS AND THERAPY MONITORING OF SYSTEMIC LUPUS ERYTHEMATOSUS Prof. Sandor Sipka, M.D., Ph.D. 3rd Department of Medicine, Institute for Internal Medicine, Medical and Health

More information

CLINICAL GUIDELINES. Summary of Literature and Recommendations Concerning Immunization and Steroid Injections Thomas J. Gilbert M.D., M.P.P.

CLINICAL GUIDELINES. Summary of Literature and Recommendations Concerning Immunization and Steroid Injections Thomas J. Gilbert M.D., M.P.P. CLINICAL GUIDELINES Summary of Literature and Recommendations Concerning Immunization and Steroid Injections Thomas J. Gilbert M.D., M.P.P. 11/2/15 Several practices routinely delay steroid injections

More information

Clinical Laboratory. 14:41:00 Complement Component 3 50 mg/dl Oct-18

Clinical Laboratory. 14:41:00 Complement Component 3 50 mg/dl Oct-18 Clinical Laboratory Procedure Result Units Ref Interval Accession Collected Received Thyroid Peroxidase (TPO) Antibody 5.0 IU/mL [0.0-9.0] 18-289-900139 16-Oct-18 Complement Component 3 50 mg/dl 18-289-900139

More information

Autoimmune Diseases. Betsy Kirchner CNP The Cleveland Clinic

Autoimmune Diseases. Betsy Kirchner CNP The Cleveland Clinic Autoimmune Diseases Betsy Kirchner CNP The Cleveland Clinic Disclosures (financial) No relevant disclosures Learning Objectives Explain the pathophysiology of autoimmune disease Discuss safe administration

More information

ORENCIA (abatacept) Demonstrates Comparable Efficacy to Humira ( adalimumab

ORENCIA (abatacept) Demonstrates Comparable Efficacy to Humira ( adalimumab ORENCIA (abatacept) Demonstrates Comparable Efficacy to Humira (adalimumab) in Patients with Moderate to Severe Rheumatoid Arthritis in First Head-to-Head Study of These Agents ORENCIA demonstrated comparable

More information

Summary Article: Lupus (Systemic Lupus Erythematosus) from Harvard Medical School Health Topics A-Z

Summary Article: Lupus (Systemic Lupus Erythematosus) from Harvard Medical School Health Topics A-Z Topic Page: Systemic Lupus Erythematosus Summary Article: Lupus (Systemic Lupus Erythematosus) from Harvard Medical School Health Topics A-Z What Is It? Lupus is thought to develop when the immune system

More information

Definition Chronic autoimmune disease The body s immune system starts attacking itself Can affect most organs and tissues in the body Brain, lungs, he

Definition Chronic autoimmune disease The body s immune system starts attacking itself Can affect most organs and tissues in the body Brain, lungs, he LIVING WITH SYSTEMIC LUPUS ERYTHEMATOSUS Stacy Kennedy, M.D.,M.B.A. Rowan Diagnostic Clinic Salisbury, N.C. May 11, 2013 Agenda What is lupus Who is affected Causes of lupus Symptoms and organ involvement

More information

University of Groningen. Weather and rheumatoid arthritis Patberg, Wiebe

University of Groningen. Weather and rheumatoid arthritis Patberg, Wiebe University of Groningen Weather and rheumatoid arthritis Patberg, Wiebe IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the

More information

New Evidence reports on presentations given at EULAR Rituximab for the Treatment of Rheumatoid Arthritis and Vasculitis

New Evidence reports on presentations given at EULAR Rituximab for the Treatment of Rheumatoid Arthritis and Vasculitis New Evidence reports on presentations given at EULAR 2011 Rituximab for the Treatment of Rheumatoid Arthritis and Vasculitis Report on EULAR 2011 presentations Anti-TNF failure and response to rituximab

More information

Association of anti-mcv autoantibodies with SLE (Systemic Lupus Erythematosus) overlapping with various syndromes

Association of anti-mcv autoantibodies with SLE (Systemic Lupus Erythematosus) overlapping with various syndromes International Journal of Medicine and Medical Sciences Vol. () pp. 21-214, June 211 Available online http://www.academicjournals.org/ijmms ISSN 2-972 211 Academic Journals Full Length Research Paper Association

More information

Mechanisms of Autontibodies

Mechanisms of Autontibodies Mechanisms of Autontibodies Production in Rheumatic Diseases Eisa Salehi PhD Tehran University of Medical Sciences Immunology Department Introduction Rheumatic diseases: Cause inflammation, swelling, and

More information

- Active rheumatoid arthritis in adult patients where treatment with disease modifying antirheumatic drugs (DMARD) is indicated.

- Active rheumatoid arthritis in adult patients where treatment with disease modifying antirheumatic drugs (DMARD) is indicated. PUBLIC SUMMARY OF RISK MANAGEMENT PLAN (RMP) TREXAN 25 MG/ML, SOLUTION FOR INJECTION, PRE-FILLED SYRINGE ORION CORPORATION DATE: 12-01-2015, VERSION 1.2 VI.2 Elements for a Public Summary Methotrexate

More information

Patient #1. Rheumatoid Arthritis. Rheumatoid Arthritis. 45 y/o female Morning stiffness in her joints >1 hour

Patient #1. Rheumatoid Arthritis. Rheumatoid Arthritis. 45 y/o female Morning stiffness in her joints >1 hour Patient #1 Rheumatoid Arthritis Essentials For The Family Medicine Physician 45 y/o female Morning stiffness in her joints >1 hour Hands, Wrists, Knees, Ankles, Feet Polyarticular, symmetrical swelling

More information

Efficacy and Safety of Rituximab in the Treatment of Rheumatoid Arthritis and ANCA-associated Vasculitis

Efficacy and Safety of Rituximab in the Treatment of Rheumatoid Arthritis and ANCA-associated Vasculitis New Evidence reports on presentations given at ACR/ARHP 2010 Efficacy and Safety of Rituximab in the Treatment of Rheumatoid Arthritis and ANCA-associated Vasculitis Report on ACR/ARHP 2010 presentations

More information

Open Access NY, USA. Keywords: HAQ, early RA, disease activity, DAS, cohort, correlation, longitudinal.

Open Access NY, USA. Keywords: HAQ, early RA, disease activity, DAS, cohort, correlation, longitudinal. Send Orders for Reprints to reprints@benthamscience.net 58 The Open Rheumatology Journal, 2013, 7, 58-63 Open Access The Relationship Between Function and Disease Activity as Measured by the HAQ and DAS28

More information

Editing file. Color code: Important in red Extra in blue. Autoimmune Diseases

Editing file. Color code: Important in red Extra in blue. Autoimmune Diseases Editing file Color code: Important in red Extra in blue Autoimmune Diseases Objectives To know that the inflammatory processes in autoimmune diseases are mediated by hypersensitivity reactions (type II,

More information

New Evidence reports on presentations given at EULAR Tocilizumab for the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis

New Evidence reports on presentations given at EULAR Tocilizumab for the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis New Evidence reports on presentations given at EULAR 2011 Tocilizumab for the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis Report on EULAR 2011 presentations Benefit of continuing

More information

Rituximab (Rituxan )

Rituximab (Rituxan ) Rituximab (Rituxan ) How does it work? Rituximab is a biologic medicine that helps keep the immune system from attacking healthy tissues in the body. Rituximab is used to treat the person with moderate

More information

Autoimmunity & Transplantation. Dr. Aws Alshamsan Department of Pharmaceu5cs Office: AA87 Tel:

Autoimmunity & Transplantation. Dr. Aws Alshamsan Department of Pharmaceu5cs Office: AA87 Tel: Autoimmunity & Transplantation Dr. Aws Alshamsan Department of Pharmaceu5cs Office: AA87 Tel: 4677363 aalshamsan@ksu.edu.sa Learning Objectives By the end of this lecture you will be able to: 1 Recognize

More information

Immunology. Lecture- 8

Immunology. Lecture- 8 Immunology Lecture- 8 Immunological Disorders Immunodeficiency Autoimmune Disease Hypersensitivities Immunodeficiency 1. Immunodeficiency --> abnormal production or function of immune cells, phagocytes,

More information

All animals have innate immunity, a defense active immediately upon infection Vertebrates also have adaptive immunity

All animals have innate immunity, a defense active immediately upon infection Vertebrates also have adaptive immunity 1 2 3 4 5 6 7 8 9 The Immune System All animals have innate immunity, a defense active immediately upon infection Vertebrates also have adaptive immunity Figure 43.2 In innate immunity, recognition and

More information

Blood Lecture Test Questions Set 2 Summer 2012

Blood Lecture Test Questions Set 2 Summer 2012 Blood Lecture Test Questions Set 2 Summer 2012 1. Leukocytes are attracted to a site of injury or disease by: a. diapedesis b. chemotaxis c. leukocytosis d. heparin e. leukomotosis 2. Leukocytes leave

More information

Is it Autoimmune or NOT! Presented to AONP! October 2015!

Is it Autoimmune or NOT! Presented to AONP! October 2015! Is it Autoimmune or NOT! Presented to AONP! October 2015! Four main jobs of immune system Detects Contains and eliminates Self regulates Protects Innate Immune System! Epithelial cells, phagocytic cells

More information

Polymyalgia rheumatica and giant cell arteritis

Polymyalgia rheumatica and giant cell arteritis Polymyalgia rheumatica and giant cell arteritis What is polymyalgia rheumatica? Polymyalgia rheumatica is a rheumatic disorder associated with moderate-to-severe musculoskeletal pain and stiffness in the

More information

SCIENTIFIC DISCUSSION

SCIENTIFIC DISCUSSION European Medicines Agency London, 20 September 2007 Product name: Remicade Procedure number: EMEA/H/C/240/II/95 SCIENTIFIC DISCUSSION 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20)

More information

Comparison between ESR and C-Reactive Protein(CRP) as a Marker of Disease activity in Patients with Rheumatoid Arthritis

Comparison between ESR and C-Reactive Protein(CRP) as a Marker of Disease activity in Patients with Rheumatoid Arthritis Original Article Comparison between ESR and C-Reactive Protein(CRP) as a Marker of Disease activity in Patients with Rheumatoid Arthritis Ali M.E. Yousef 1, Fatemah A. Elshabacy 2, Sherry K. Abdelrahman

More information

Benlysta (belimumab) Prior Authorization Criteria Program Summary

Benlysta (belimumab) Prior Authorization Criteria Program Summary Benlysta (belimumab) Prior Authorization Criteria Program Summary This prior authorization applies to Commercial, NetResults A series, NetResults F series and Health Insurance Marketplace formularies.

More information

Rheumatoid Arthritis. Rheumatoid Arthritis. RCS 6080 Medical and Psychosocial Aspects of Rehabilitation Counseling. Rheumatic Diseases

Rheumatoid Arthritis. Rheumatoid Arthritis. RCS 6080 Medical and Psychosocial Aspects of Rehabilitation Counseling. Rheumatic Diseases RCS 6080 Medical and Psychosocial Aspects of Rehabilitation Counseling Rheumatic Diseases The prevalence of rheumatoid arthritis in most Caucasian populations approaches 1% among adults 18 and over and

More information

Cell-Mediated Immunity and T Lymphocytes

Cell-Mediated Immunity and T Lymphocytes Cell-Mediated Immunity and T Lymphocytes T helper (Th) Cells Peripheral lymhoid tissue thymus Lymphoid stem cell CD8+ CD4+ CD4+ Treg CD8+ CTL + antigen Cytotoxic T lymphocyte CD4+ Th Helper T cell CD4+

More information

Deciding what to do about Rheumatoid Arthritis

Deciding what to do about Rheumatoid Arthritis Shared Decision Making rheumatoid arthritis Next clinical review date March 2018 Deciding what to do about Rheumatoid Arthritis This short decision aid is to help you decide what treatment to have if you

More information

Subject: Remicade (Page 1 of 5)

Subject: Remicade (Page 1 of 5) Subject: Remicade (Page 1 of 5) Objective: I. To ensure that Health Share/Tuality Health Alliance (THA) has a process by which the appropriate utilization of Remicade (Infliximab) for members whose diagnosis

More information

Effective Health Care Program

Effective Health Care Program Comparative Effectiveness Review Number 28 Effective Health Care Program Disease-Modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA) Executive Summary Background

More information

Complement in vasculitis and glomerulonephritis. Andy Rees Clinical Institute of Pathology Medical University of Vienna

Complement in vasculitis and glomerulonephritis. Andy Rees Clinical Institute of Pathology Medical University of Vienna Complement in vasculitis and glomerulonephritis Andy Rees Clinical Institute of Pathology Medical University of Vienna 41 st Heidelberg Nephrology Seminar March 2017 The complement system An evolutionary

More information

The Rheumatoid Hand Deformities & Management. Dr. Anirudh Sharma Resident Department of Orthopedics

The Rheumatoid Hand Deformities & Management. Dr. Anirudh Sharma Resident Department of Orthopedics + The Rheumatoid Hand Deformities & Management Dr. Anirudh Sharma Resident Department of Orthopedics + Why is Rheumatoid Arthritis important? + RA is a very debilitating disease median life expectancy

More information

ACTEMRA (tocilizumab)

ACTEMRA (tocilizumab) RATIONALE FOR INCLUSION IN PA PROGRAM Background Actemra is an agent in the class of drugs known as biologic disease modifiers. It is used to treat adult onset rheumatoid (RA) arthritis, polyarticular

More information

PLASMAPHERESIS IN RESPIRATORY DISTRESS SYNDROME

PLASMAPHERESIS IN RESPIRATORY DISTRESS SYNDROME 1 IN RESPIRATORY DISTRESS SYNDROME In respiratory distress syndrome (RDS) underlies toxic edema of the lungs due to endotoxicosis, complicating the course of acute pneumonia and infectious destructions

More information

Autoimmune disorders: An emerging risk factor for CV disease

Autoimmune disorders: An emerging risk factor for CV disease Autoimmune disorders: An emerging risk factor for CV disease DR. SHARON MULVAGH: Greetings. I'm Dr Sharon Mulvagh, professor of medicine and director of Mayo Clinic Women's Heart Clinic. During today's

More information

Immunity to Viruses. Patricia Fitzgerald-Bocarsly September 25, 2008

Immunity to Viruses. Patricia Fitzgerald-Bocarsly September 25, 2008 Immunity to Viruses Patricia Fitzgerald-Bocarsly September 25, 2008 The Immune System Deals with a Huge Range of Pathogens Roitt, 2003 Immune Responses to Viruses Viruses are dependent on the host cell

More information

Title: Predictive factors of relapse, in patients with JIA in remission, after discontinuation of synthetic disease-modifying antirheumatic drugs.

Title: Predictive factors of relapse, in patients with JIA in remission, after discontinuation of synthetic disease-modifying antirheumatic drugs. Title: Predictive factors of relapse, in patients with JIA in remission, after discontinuation of synthetic disease-modifying antirheumatic drugs. Background Juvenile idiopathic arthritis (JIA) is not

More information

Autoantibodies against oxidized low-density lipoprotein (LDL) and carotid atherosclerosis in patients with rheumatoid arthritis

Autoantibodies against oxidized low-density lipoprotein (LDL) and carotid atherosclerosis in patients with rheumatoid arthritis Autoantibodies against oxidized low-density lipoprotein (LDL) and carotid atherosclerosis in patients with rheumatoid arthritis Y. Wada 1, T. Kuroda 1, A. Murasawa 4, N. Tanabe 2, M. Nakano 3, F. Gejyo

More information

Department of Studies & Planning, Statistics Section, The Research Council, Muscat 130, Oman

Department of Studies & Planning, Statistics Section, The Research Council, Muscat 130, Oman International Rheumatology Volume 2012, Article ID 285854, 5 pages doi:10.1155/2012/285854 Clinical Study Evaluation of Anti-Mutated Citrullinated Vimentin Antibodies, Anti-Cyclic Citrullinated Peptide

More information

Scintigraphic Findings and Serum Matrix Metalloproteinase 3 and Vascular Endothelial Growth Factor Levels in Patients with Polymyalgia Rheumatica

Scintigraphic Findings and Serum Matrix Metalloproteinase 3 and Vascular Endothelial Growth Factor Levels in Patients with Polymyalgia Rheumatica The Open General and Internal Medicine Journal, 29, 3, 53-57 53 Open Access Scintigraphic Findings and Serum Matrix Metalloproteinase 3 and Vascular Endothelial Growth Factor Levels in Patients with Polymyalgia

More information

MMS Pharmacology Lecture 2. Antirheumatic drugs. Dr Sura Al Zoubi

MMS Pharmacology Lecture 2. Antirheumatic drugs. Dr Sura Al Zoubi MMS Pharmacology Lecture 2 Antirheumatic drugs Dr Sura Al Zoubi Revision Rheumatoid Arthritis Definition (RA): is the most common systemic inflammatory disease characterized by symmetrical inflammation

More information

Policy. Section: Medicine Effective Date: January 15, 2015 Subsection: Pathology/Laboratory Original Policy Date: December 5, 2014 Subject:

Policy. Section: Medicine Effective Date: January 15, 2015 Subsection: Pathology/Laboratory Original Policy Date: December 5, 2014 Subject: Last Review Status/Date: December 2014 Page: 1 of 10 Summary Systemic lupus erythematosus (SLE) is an autoimmune connective tissue disease that can be difficult to diagnose because patients often present

More information